Latest News

The Phase 1 study forms part of an expanded collaboration between Moderna and the Coalition for Epidemic Preparedness Innovations (CEPI).

Under the definitive agreement, KKR will acquire all outstanding shares of Integer Holdings for US$127 per share in cash.

More than 600 delegates are expected to attend the Region’s main annual forum for health governance and policymaking.

The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the fourth quarter of 2026.

The partnership will support Nigeria’s post-marketing vaccine surveillance system by evaluating innovative screening devices and expanding routine laboratory testing for vaccine lots.

Its educational programs cover pediatric dentistry, airway health, sleep-disordered breathing, oral function, early facial growth, interceptive orthodontics and myofunctional therapy.

The decision follows the failure of the phase 3 Lagoon trial, which did not meet its primary endpoint of overall survival.

The government gazetted the new status on July 24, 2026, marking a significant step in the development of specialised infectious disease services, research and training in the country.

The test could also help clinicians identify patients who are unlikely to benefit from immunotherapy before treatment begins, potentially allowing them to consider alternative therapies sooner.

The partnership will unlock KSh10.4 billion (US$80 million) over the next five years to accelerate implementation of Kenya’s Every Woman Every Newborn Everywhere (EWENE) Acceleration Plan and support the country’s 90-90-80-80 maternal and newborn health targets.